Takeda obtains EC approval for tetravalent dengue vaccine Qdenga
The European Commission (EC) approved Qdenga (TAK-003) for use in individuals aged four years and above, administered subcutaneously…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
09 Dec 22
The European Commission (EC) approved Qdenga (TAK-003) for use in individuals aged four years and above, administered subcutaneously…
08 Dec 22
Pfizer has received the FDA’s Prescription Drug User Fee Act (PDUFA) goal date of May 2023, for a…
02 Dec 22
Rezlidhia is an oral, small molecule, indicated for the treatment of adults with relapsed or refractory (R/R) AML…
28 Nov 22
The Taiwan Food and Drug Administration has granted accelerated approval designation (AAD), and South Korea’s Ministry of Food…
24 Nov 22
Skyrizi is a humanised monoclonal antibody inhibitor that selectively targets interleukin-23 (IL-23), a cytokine involved in inflammatory processes,…
23 Nov 22
Hemgenix is a gene therapy that promotes continuous production of factor IX to reduce abnormal bleeding in people…
21 Nov 22
The expanded approval adds new dosing options for Rylaze, which provides sustained asparaginase activity for adult and paediatric…
18 Nov 22
TZIELD is an anti-CD3-directed antibody, indicated for administration as a once-daily intravenous infusion for 14 days, to delay…
14 Nov 22
The FDA approval is supported by positive results from the Phase 3 POSEIDON study, which showed a significant…
11 Nov 22
VidPrevtyn Beta is a monovalent, recombinant-protein, next-generation Covid-19 vaccine developed by Sanofi, leveraging GSK’s pandemic adjuvant, and is…